Kohler S, et al. - This research scrutinized the impact of empagliflozin on bone fractures and bone mineral density in patients with type 2 diabetes in pooled placebo-controlled trial data and a head-to-head study vs glimepiride. Researchers analyzed pooled data from subjects who were randomized 1:1:1 to empagliflozin 10 mg, empagliflozin 25 mg, or placebo in phase I–III clinical trials. In addition, data were analyzed from the EMPA-REG H2H-SU trial in which subjects received empagliflozin 25 mg or glimepiride as an add-on to metformin for 104 weeks with a 104-week extension. It was noted that empagliflozin did not increase the risk of bone fracture compared with placebo in a pooled analysis of >12,000 patients or compared with glimepiride in a 4-year head-to-head study.